The devil’s in the details: Navigating complexity & nuance in global trial contracts
Clinical trial sponsors and contract research organisations (CROs) are expanding clinical trials internationally to access diverse patient populations and enhance competitiveness.
The global clinical trials market size was estimated at $83.75 billion in 2024 and is projected to reach $149.58 billion by 2034, growing at a compound annual growth rate of 6.10%. Emerging markets are playing a significant role in global clinical research, accounting for a much larger share of trial activity than the early estimate of 13%. Countries such as India, Brazil, and Colombia have become attractive destinations due to growing economies, large patient populations, and improved healthcare infrastructure. In particular, the Asia-Pacific region has seen clinical trial participation increase by about 10% over the past five years and is now considered the fastest-growing market.
However, expansion introduces operational complexity and increased risk, as each country has distinct regulatory requirements and contractual expectations. Sponsors and CROs that proactively address these challenges upfront are better positioned for successful study execution.
The myth of regional standardisation
Each country has unique regulatory documentation, agreement templates, negotiation frameworks, and communication norms. Failing to understand these differences in advance can increase costs, delay site activation, extend negotiation timelines, and – maybe most importantly – harm site relationships.
Contract processes differ significantly by country and, in some cases, by institution. For example, within Europe:
- Spain may require regionally developed hospital-specific contract templates that are treated as non-negotiable at the institutional level.
- Romania requires hospital-specific Clinical Trial Agreements (CTA) for submission.
- France mandates specific national budget formatting, requiring sponsor-developed budgets to be transcribed into a country-prescribed structure.
Meanwhile, Japan uses site-driven templates and negotiation systems that differ from those in China. South Korea imposes sequencing requirements that significantly affect timeline planning. And more.
Relying on regional playbooks for global contracting is unsustainable, given operational realities.
“The reality is that there is no standardised contracting template that works across all countries. Even if you use your own template, every site has its own requirements that they will insert into contracts,” Melissa Long, Xencor senior director of contracts & data privacy, explains. Xencor, by way of example, is a clinical-stage biopharmaceutical company advancing engineered antibodies for the treatment of patients with cancer and autoimmune diseases.
No global order of operation for negotiation
In the United States, many sponsors and CROs are accustomed to parallel processing, as many sites are willing to begin contract discussions before full regulatory approval of a protocol. But the same is not true in many other regions.
In many European countries, sites will not begin contract discussions until regulatory documentation is complete and approved. They require confirmation of regulatory approval and Letters of Authorisation (LOAs) or similar approvals before committing internal resources.
South Korea adds further complexity, as the budget must be negotiated and finalised before submission to the local ethics committee. Any budget misalignment can delay both regulatory review and site activation.
Sponsors that insist on imposing the American style of “negotiate first, finalise later” approach abroad will often face resistance. Foreign sites will simply not engage until prerequisites are met. Without understanding these processes in advance, sponsors risk creating unrealistic timelines.
“Given the complexities, it is crucial to prepare in advance including outlining how you want things to go and knowing what templates you want to use, but most importantly seek the expertise of an experienced partner,” notes Long. “Arm yourself with the local, legal resources to swiftly handle the up-front contracts, as well as the downstream negotiation where they know the language, the cultural nuances, the time zone, and local laws.”
Clinical Trial Agreement templates and budget fragmentation
US-based sponsors and CROs typically rely on standardised Clinical Trial Agreement (CTA) templates. However, outside the US, template fragmentation is common. Multiple layers may exist, including:
- Sponsor/CRO-developed templates
- National country templates
- Country preferred by sites, but not legally required templates
- Hospital templates are unique to each institution
For example, in Spain and Japan, individual hospitals may require their own contract formats. In Romania, hospital-specific versions are mandatory for submission. In France, budget documents must follow national formatting rules, and some countries require formal budget splits between the institution and the principal investigator. In Portugal, in addition to the CTA, many sites also require a separate financial agreement – typically, a site-level template that allows only minor modifications. Even when financial terms are already covered in the CTA, sites may still require this additional agreement to formalise payment details.
Further complicating the process, the budget and contract are often reviewed separately during negotiations. Legal departments review contractual language, while finance or clinical operations teams assess the budget. These are consolidated into a single executed CTA, which must then be submitted to the regulatory authority in many countries.
This separation can cause friction if assumptions are not aligned. Changes in budget language may reopen contract negotiations, and mandated templates can override sponsor-preferred language. For instance, in Spain, local negotiators should review and populate site and hospital CTA templates with study- and sponsor-specific information to ensure accurate translations. Local teams should also review a site's budget templates and adopt in accordance with the protocol to ensure the templates are aligned.
When going global, what seems like a simple document negotiation is actually a complex, multi-departmental and multi-regulatory coordination effort.
A costly miscalculation: Negotiable vs non-negotiable terms
A key challenge in global contracting is distinguishing between legal requirements and operational preferences.
For example, a hospital template in Spain may be considered non-negotiable at the institutional level, even if not required by national law. Japanese sites may insist on institution-specific provisions. In these situations, insisting on sponsor-standard language can damage relationships.
In one recent example, sites in Turkey demanded reimbursement for hospitalisation fees that sponsors considered standard-of-care expenses, expected to be covered by patient insurance. When the sponsor resisted, sites threatened to withdraw from the study.
If a site withdraws, it can disrupt enrolment projections, extend timelines, increase budgets, and affect expectations. Sponsors also value long-term site relationships, and adversarial contract negotiations can harm future collaboration.
Proactively understanding legal requirements, customs, and preferences reduces the risk of late-stage conflict. When issues arise, immediate transparency and alignment are essential to maintain timelines and relationships.
“Today, more than ever, sponsors must protect the site relationship, and this is just as important outside of the US as it is within our borders,” warns Long. “Many of today’s clinical trials are in disease areas or indications that are very complex, so there is often a limited number of experienced, trusted sites. Sponsors must be flexible on the terms to establish long-term relationships.”
Communication is not simply language… It’s process
Communication norms vary widely by country and can significantly affect responsiveness, clarity, and trust when followed appropriately.
In South Korea, negotiations may occur in English, but formal correspondence is expected in Korean. Understanding translation requirements and timing is critical. Missteps can delay responses or indicate a lack of local awareness.
In other regions, communication cadence also varies. Some countries require formal written exchanges at specific stages, while others use centralised site networks. Some hospitals and investigators in Europe – particularly in Hungary, Poland, and Turkey – prefer to communicate via phone for most of the negotiations, while other countries prefer written email communication. Knowing how sites typically operate allows local teams to approach them initially through their preferred method of communication, reducing the time waiting for a response and helping to establish good rapport with sites from the start.
“It is challenging to have this level of on-the-ground knowledge globally, so, experienced partners that are focused solely on the business of trials and maintain reliable, local connections in the regions where eligible patients reside are a valuable resource,” Long advises.
From administrative task to critical lever
Clinical trial contracts are often seen as administrative documents, but they can be strategic tools that directly affect activation timelines, cost control, and site retention. Local knowledge and expertise enable sponsors and CROs to:
- Understand documentation sequencing before timelines are finalised
- Prepare correct template versions for regulatory submission
- Anticipate non-negotiable institutional provisions
- Avoid unnecessary negotiation cycles
- Protect & improve long-term site relationships
Reducing negotiation timelines is not only about speed, but also about predictability. Transparent, proactive engagement minimises late-stage surprises that can disrupt activation schedules. In addition, smooth CTA negotiations go far to deepen relationships with hard-to-find sites. In the Czech Republic, for instance, sites utilise either a sponsor CTA template or the country’s CTA template. Only experienced local teams can predict what each site's preference will be, preparing the CTA based on the site’s preferred template up front to expedite their review. However, some countries still prefer a more personal touch, such as Georgia, where local negotiators succeed by presenting sites with hard copies of the final CTA to obtain their signatures, instead of emailing it and waiting for a protracted response.
As global clinical development expands, contract localisation has become a strategic differentiator, rather than a back-office task.
The way forward
Global contracting can be a competitive advantage, especially if integrated into early study planning, timeline forecasting, and market selection. Organisations that incorporate local insight before drafting documents and circulating budgets gain measurable advantages in predictability, cost control, and long-term site partnerships.
“Many [of our] trials today have global components,” shares Long. “Partners that specialise in global contracting allow us to reach the right patients worldwide and keep to timelines.”
In a competitive research landscape, country-level operational expertise turns global ambition into practical execution.
About the author
Jenna Lucchesi is executive director of contracts management for Ledger Run, developer of a comprehensive clinical trial financial operations platform.
